IBJNews

Company news

March 10, 2014
Keywords
Back to TopE-mailPrintBookmark and Share

Dow AgroSciences LLC predicts its $7 billion in annual sales will double over the next five to 10 years as it launches 13 new products by 2018. The biggest of those products is expected to be its Enlist Weed Control System, which is set to hit markets in 2015. Enlist kills weeds that have grown resistant to glyphosate, the active ingredient in the popular Roundup herbicide developed by competitor Monsanto Co. The new products stem from a bevy of R&D activity at Dow Agro’s headquarters at West 96th Street and Zionsville Road. The company had nearly 3,500 patents worldwide at the end of 2013, up from 2,800 just a year earlier, according to Securities and Exchange Commission filings. The global market for agricultural technology is valued at $100 billion and is set to explode as the human population swells from the current 7 billion to an anticipated 9 billion by 2050.

The University of Indianapolis is negotiating with developers to finance a $22 million to $30 million health sciences center adjacent to its south-side campus. UIndy would be the main tenant in the 134,000-square-foot building, which is slated to open in August 2015 on the southwest corner of Hanna and State avenues. UIndy officials declined to name the developers it is talking to, but said it would select one this spring. In addition, UIndy plans to release a request for proposals at the end of March to health agencies or hospital systems to potentially open clinical space in the center or operate a partnership with the university to study and improve health disparities in the city and state. On a parallel track, UIndy is talking to other health care providers about opening a presence in the new building. According to UIndy President Robert Manuel, the school has had talks with one provider that operates 250 clinics around the Midwest. Roughly 34,000 square feet of the building is earmarked for those partners, Manuel said.

Empagliflozin, a diabetes pill developed by Eli Lilly and Co. and Boehringer Ingelheim GmbH, was rejected by U.S. regulators because of unresolved manufacturing deficiencies at a German plant, Bloomberg News reported. The U.S. Food and Drug Administration inspected Boehringer’s Ingelheim am Rhein facility in 2012 and warned the company of the faults in May 2013. No new clinical studies will be needed to approve the drug. The FDA re-inspection of Boehringer’s plant is continuing, said company spokeswoman Emily Baier. It could take up to six months after the inspection for the FDA to decide whether the problems have been fixed. Empagliflozin is part of a class of drugs that includes Johnson & Johnson’s Invokana and AstraZeneca Plc’s Forxiga. The drugs help the body get rid of sugar through the kidneys. The Lilly-Boehringer drug is projected to reach sales of $295 million for Lilly in 2019, according to analyst estimates compiled by Bloomberg.

A moratorium on the construction of nursing homes in Indiana is now in a legislative conference committee, where lawmakers will seek a compromise between a five-year Senate version and a one-year version passed by the House. Rep. Tim Brown, R-Crawfordsville, said the moratorium called for in Senate Bill 173—through June 30, 2015—would save money for the state, as well as nursing home facilities, according to The Statehouse File. Hospitals and facilities with fewer than 10 beds would be exempt from the moratorium. The bill would not affect assisted-living homes or the transfer of Medicaid beds. Brown said Indiana's nursing homes aren’t full and that the state is paying a part of those fixed costs. But Rep. Todd Huston, R-Fishers, called the bill an “over-the-top solution to a market-based problem.”

Health insurers such as Indianapolis-based WellPoint Inc. and Louisville-based Humana Inc. stand to receive $5.5 billion next year to cover losses from Obamacare in a program the law’s opponents label a bailout, according to Bloomberg News. The money, outlined in President Barack Obama’s proposed budget for the fiscal year that begins in October, is designated to help insurers who find the cost of the law higher than expected, based on the percentage of older, sicker people who sign up compared with younger enrollees. Under the Patient Protection and Affordable Care Act, insurers who record a profit of 3 percent or more on their Obamacare business would put some of the gains into a government-controlled fund. Companies whose claims cost at least 3 percent more than their premium revenue can access the money. The administration expects to collect enough from profitable insurers to cover the costs of payments to other companies in the risk corridors program, Emily Cain, a spokeswoman for the U.S. Office of Management and Budget, said in an email.

ADVERTISEMENT

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Paul (2014-04-14 17:53:08) My name is Mr Paul Ferdinand, i am from Chicago USA, married, i have been searching for a genuine loan company for the past 3 months and all i got was bunch of scams who made me to trust them and at the end of the day, they took my money without giving anything in return, all my hope was lost, i got confused and frustrated,i find it very difficult to feed my family, i never wanted to have anything to do with loan companies on net, so went to borrow some money from a friend, i told him all that happened and he said he can help me, that he knows a loan company that can help me, that he just got a loan from them, he directed me on how to apply for the loan, i did as he told me, i applied, i never believed but i tried and to my greatest surprise i got the loan within 24 hours, i could not believe, i am happy and rich again and i am thanking God that such loan companies like this still exist upon this scams all over the places, please i advise everyone out there who are in need of loan to go to richardstrustfunds@gmail.com they will never fail, your life shall change as mine did.

  2. What became of this project? Anyone know?

  3. Scott, could you post an enlarged photo of the exterior of the building? This will be a great addition to Walnut Street. This area will only continue to develop with additions like this. Also, please give us more updates on the "Cultural Trail light" expansion. Also a great move for the city, as long as there is maintenance money set aside.

  4. Great story IBJ! Citizens don't have a real sense of the financial magnitude of supporting Indy's sports and tourism sector. The CIB was a brilliant idea for creating a highly integrated public-private partnership to support this sector from the economic activity it generates. Unfortunately, most folks think the benefits of that economic activity accrue directly to the City budget, and it doesn't. So though the CIB is facing lean times (covering its costs while maintaining minimally acceptable reserves), the City is operating with deficit - less tax revenue than expenses each year - with a very fragile reserve balance. That's why it's so challenging for the City to fund basic needs or new intitatives (e.g. pre-k education; new jail), and some credit rating agencies have downgraded Indy from it's past stellar AAA status. More reporting on City finances would be welcomed.

  5. Sure, I'll admit that it bugs me to see that the IBJ.COM censors it's blog posts almost as much as the D of I does when someone points out the falsehoods and fabrications. _____But I think it bothers me almost as much that Captain/Defender/Disciple get his yanked too. You see, those of us with a sense of integrity, humanity, compassion, and a need for fact based opinion WANT to see all of his screeds posted. It makes our point so much better than we can do it ourselves.

ADVERTISEMENT